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ABSTRACT This study aimed to estimate time trends in the lifetime risk of hospitalisation with
exacerbation of chronic obstructive pulmonary disease (COPD) in Denmark.
During the period from 1994 to 2008, a register-based cohort study was conducted covering each subject
in the entire population of Denmark (5.18 million in 2008). Based on previously validated diagnosis codes,
all COPD hospitalisations were identified. Individual retrospective review periods of 8 years were used to
determine first-time hospitalisations. From year 2002 to 2008, all first-time COPD hospitalised subjects
aged o30 years were identified. The calculation of lifetime risk was based on age- and sex-specific first-time
COPD hospitalisation rates and rates of COPD hospitalisation-free survival, assuming them to be calendar
time stationary.
The study included 23.9 million person-years of risk time and identified 48 959 first-time COPD
hospitalisations. For 30-year-olds in Denmark, the lifetime risk of COPD hospitalisation was 12.0% (95% CI
11.9–12.2) for females and 10.9% (95% CI 10.8–11.1) for males. Trends were generally equal in both sexes.
During the period from 2002 to 2008, the rate of first-time COPD hospitalisations decreased, while the
survival of never COPD hospitalised subjects increased. In consequence, the lifetime risk of COPD
hospitalisation remained constant.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable disease, but the exposure to inhaled gases
and particles, e.g. tobacco smoke, which is the major cause of the disease, usually begins decades before
symptomatic disease can be detected [1]. Because of this temporal detachment of cause and effect and
because not all smokers live to develop the disease, risk estimates of developing the disease are important to
individual preventive counselling. Also, for healthcare planners, risk estimates are needed to anticipate its
future burden and to prioritise prevention resources between COPD and other preventable health risks.
Risk is preferably estimated as the age-specific incidence rates. However, the full spectrum of age-specific
incidence rates is difficult to communicate to patients and politicians, and also to compare across countries
and diseases. Furthermore, the risk of developing a chronic disease, such as COPD, at some future age (the
age-specific incidence rate) provides little information to a patient, if the chances of surviving until that age
without already having developed the disease are not considered.
Lifetime risk estimates overcome this problem by summing up the spectrum of age-specific incidence rates
and the rates of disease-free survival into one single number [2, 3]. Such estimates are commonly used
benchmarks with regard to other chronic diseases, such as cardiovascular disease and cancer, but they have
not until recently been adopted in COPD [4, 5].
The few previous COPD lifetime risk studies [6–8] have not focused on the risk of developing the end stages
of COPD, in which mortality, quality of life reduction and healthcare costs are highest, and hospitalisations
with exacerbation of the disease are frequent [9–12].
This study aimed to estimate time trends in the lifetime risk of hospitalisation with COPD in Denmark.
Methods
Design
During the period from January 1, 1994 to December 31, 2008, a register-based cohort study was conducted
covering each subject in the entire population of Denmark (5.18 million in 2008 [13]).
Data sources
In Denmark, healthcare services are in general free of charge and with equal access for all citizens. COPD
hospitalisations are to public hospitals and occur either by referral from a general practitioner or, in severe
cases, as direct emergency admissions.
Since 1977, the Danish National Patient Registry has recorded administrative data from all Danish
admissions to hospital [14]. From 1994 and onwards, diagnoses are classified according to the International
Classification of Diseases 10th revision (ICD-10) [15]. All data are registered with the patient’s unique civil
registration number, which allows data linkage on an individual level between all national registers [16].
We identified all hospitalisations with COPD in Denmark during the years 1994 to 2008, and linked the
individual health administrative data with data from the Demographic Register regarding the patients’ dates
of birth, death, and migrations to or from Denmark. For the years 2002 to 2008, the Demographic Register
also provided age- and sex-specific numbers of subjects and deaths in the total Danish population.
Definition of hospitalisation with COPD
COPD hospitalisation was defined as any hospitalisation with either ICD-10 codes J41–44 (COPD, chronic
bronchitis or emphysema) as primary diagnosis or with J13–18 (pneumonia) or J96 (respiratory failure) as
primary diagnosis combined with J41–44 as a secondary diagnosis.
Except for the inclusion of J41–43, the aforementioned combinations of diagnosis codes are used in the
Danish healthcare system to monitor and pay for the hospital treatment of COPD, and a 2008 nationwide
validation study found a 93% positive predictive value for J44 as primary diagnosis and 87% as secondary to
respiratory failure or pneumonia [14]. The inclusion of J41–43 (chronic bronchitis and emphysema) was
suggested in the validation paper to obtain the best possible sensitivity and specificity. In a prior study, we
showed that hospitalisations coded with J41–43 did not significantly differ from those coded with J44
(COPD) [17]. Sensitivity analyses leaving out pneumonia as primary diagnosis and exclusively including J44
as primary diagnosis were conducted.
Definition of incident and prevalent cases
First-time COPD hospitalisations (incident cases) were defined as any COPD hospitalisation of a subject
who had not been hospitalised with COPD within a period of 8 years before the hospitalisation in question.
Correspondingly, subjects were classified as prevalent cases between first COPD hospitalisation and death,
migration, or the end of 8 years of individual follow-up with no COPD hospitalisations (whichever
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occurred first). The 7-year study period and the longer 8-year retrospective review period were chosen
because ICD-10 classified data were only available from year 1994 to 2008, and we wanted both unbiased
trend estimates and to avoid the possibility of the same subject being regarded as first-time hospitalised
twice in our study period. Sensitivity analyses as to the length of the retrospective review period were
performed, reducing it to 5 years in the overall estimate and increasing it to 14 years, which was only
possible in year 2008.
Estimation of lifetime risk
On January 1 each year from 2002 to 2008, all Danish subjects aged o30 years were categorised as being
either prevalent or at risk of first-time COPD hospitalisation. For each calendar year, all subjects at risk in
the beginning of the year were further categorised as having either died or been hospitalised with COPD
(whichever occurred first), or as remaining at risk throughout the year. Using 1-year age strata from age
30 years until .99 years, the age- and sex-specific number of subjects in each category was calculated for
each calendar year. The incidence rates of first-time COPD hospitalisations and the mortality rates of
subjects never hospitalised with COPD were estimated from the number of incident subjects and the
number of subjects who died before COPD hospitalisation, respectively, divided by the number of subjects
at risk in the beginning of each year.
The key to calculating the annual lifetime risk estimates is the assumption that in a future lifespan from age
30 years until .99 years, the above-mentioned age-specific incidence and mortality rates were to remain
constant. With this assumption, a method described by KEIDING [2] was used to estimate the lifetime risk of
COPD hospitalisation.
For each age from 30 years to .99 years, the probability of COPD hospitalisation-free survival from age
30 years until a given age was calculated as the product of the age-specific probabilities from age 30 years
until that given age. The conditional probability of being hospitalised with COPD at a specific age, given
COPD hospitalisation-free survival from age 30 years until that given age, was calculated as the product of
the age-specific COPD-hospitalisation-free survival probability and the incidence rate of first-time COPD
hospitalisation at the given age. Finally, the residual lifetime risk at a given age was calculated as the sum of
the above conditional probabilities from that age until age .99 years. Confidence intervals were calculated
using bootstrap techniques. All analyses were performed using STATA Release 11.0 (STATACorp, College
Station, TX, USA).
We started the calculations at age 30 years because the diagnosis codes were validated from that age
onwards and because COPD hospitalisations before that age are extremely rare. Hence, the few young adults
that we identified with a COPD diagnosis in the register may instead have had asthma, just as the more
frequent children aged 0–2 years also coded with COPD may very probably have had altogether different
airway diseases.
The study was approved by the Danish Data Protection Agency (reference number 2009-41-3337). As the
study was register-based, according to Danish legislation no approval from the Biomedical Research Ethics
Committee was required.
Results
During the period from year 2002 to 2008, the Danish population aged o30 years increased from 3.39 to
3.51 million persons and the observed cumulated person risk time for first-time COPD hospitalisation was
23.9 million person years. We identified 22 749 males with first-time COPD hospitalisations and 26 210
females. The hospitalisations of patients who were aged o45 years (97.5%) were characterised in a prior
paper; inpatient mortality increased from 5.9 to 7.0% and 1-year mortality from 23.2 to 25.9% [17].
Among Danes aged o30 years, the incidence rate of first-time COPD hospitalisations was 2.14 per 1000
person years for females (95% CI 2.11–2.16) and 1.95 for males (95% CI 1.93–1.98) (table 1). The risk of
first-time COPD hospitalisation increased with age until ,80 years for females and 85 years for males.
Above these ages, the risk decreased with increasing age (fig. 1 and table 1).
During the period from year 2002 to 2008, in both sexes, the residual lifetime risk for 30-year-olds to be
hospitalised with COPD remained roughly constant. Therefore, no further trend analyses were made. Based
on the total period, using the main case definition, the risk was 12.0% (95% CI 11.9–12.2) for females and
10.9% (95% CI 10.8–11.1) for males. Using the strictest case definition, exclusively J44 as primary diagnosis,
the risk was reduced to 9.6% in females and 8.4% in males (table 2).
The residual lifetime risk for 30-year-olds consisted primarily of the conditional probabilities between 45
and 90 years of age (fig. 2). This was because of low rates of first-time hospitalisation and hospitalisation-
free survival, respectively, below and above this age interval.
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From age 30 years, for females, the residual lifetime risk continuously decreased with increasing age. For
males, the residual lifetime risk increased slightly until age 48 years, after which it decreased. Until age
65 years, the risk was higher in females, but above that age, the male risk was higher (fig. 3 and table 3).
Extending the retrospective review period for the analysis of year 2008 from 8 to 14 years did not lower the
lifetime risk estimates substantially, while decreasing the retrospective review period to 5 years in the overall
analysis increased the lifetime risk estimate for males from 10.9% (95% CI 10.8 – 11.1) to 11.6% (95% CI
11.4 – 11.7) and for females from 12.0% (95% CI 11.9 – 12.2) to 12.8% (95% CI 12.7 – 13.0).
Discussion
This is the first study to estimate the lifetime risk of COPD hospitalisation. Data from 15 years of
continuous and complete coverage of all 5.43 million citizens of Denmark were analysed and the main
observation is that, for 30-year-old Danes, the lifetime risk of having a COPD exacerbation requiring
hospitalisation is 12% for females and 11% for males. Considering the 25% 1-year mortality and the fact
that multiple minor to moderate exacerbations as well as many years of progressive symptoms and reduced
quality of life usually precedes hospitalisation with COPD [12, 18], this study confirms that COPD is among
the most important public health problems.
Three prior COPD studies have reported lifetime risks in the general population. In Ontario, Canada, using
14 years worth of validated register data from both primary and secondary care on ,6 million subjects,
GERSHON et al. [6] reported a 26% female and 30% male risk of developing physician-diagnosed COPD. In a
similar Dutch study including ,185 000 subjects in 400 general practices spread across the country, AFONSO
et al. [8] reported a substantially lower 8.3% female and 12.7% male risk. In that study, however, all records
of potential COPD underwent expert review using a somewhat stricter case definition. In contrast to the
TABLE 1 Age- and sex-specific rates of first-time chronic obstructive pulmonary disease (COPD) hospitalisations in Denmark
during 2002–2008; main case definition
Age years Females Males
First-time
COPD
hospitalisations n
Risk time# Incidence rate
"
95% CI First-time
COPD
hospitalisations n
Risk time# Incidence
"
95% CI
30–39 293 2 735 642 0.11 0.09–0.12 222 2 811 255 0.08 0.07–0.09
40–49 1107 2 667 380 0.41 0.39–0.44 860 2 744 868 0.31 0.29–0.33
50–59 2936 2 572 971 1.14 1.10–1.18 2486 2 602 275 0.95 0.92–0.99
60–69 6059 1 982 296 3.06 2.98–3.13 5180 1 915 141 2.70 2.63–2.78
70–79 9201 1 325 121 6.94 6.80–7.08 8255 1 068 412 7.73 7.56–7.89
80–89 5824 807 149 7.16 6.98–7.35 5236 443 690 11.80 11.48–12.12
o90 790 178 549 4.42 4.12–4.73 510 56 593 9.01 8.23–9.79
Total 26 210 12 274 932 2.14 2.11–2.16 22 749 11 642 234 1.95 1.93–1.98
#: person years at risk of first-time COPD hospitalisation; ": per 1000 person years.
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FIGURE 1 Risk of first-time chronic
obstructive pulmonary disease hospital-
isation in 1 year.
COPD | J. LYKKEGAARD ET AL.
DOI: 10.1183/09031936.00129312 967
register-based studies of physician-diagnosed COPD, VAN DURME et al. [7] conducted an 11-year cohort
study. Also in the Netherlands, ,8000 COPD-free subjects were followed with spirometry every 2–3 years,
with additional follow-up in hospital and primary care and through pharmacy records. The study reported
a 16% female and 24% male risk of developing COPD.
Although the above studies differ from ours, both the assumption of constant future age-specific rates and
the basic principles of calculating lifetime risk are similar. However, due to the high frequency of fatal
comorbidities and the slow progression of the disease, many patients with early stages of COPD will die
from other causes before hospitalisation with COPD is required. Also, some patients develop fatal COPD,
although they are never hospitalised with the disease. Hence, compared with the risks found in this present
study, the aforementioned risks are higher, simply because the patients were diagnosed at earlier milder
stages of the disease. The latter is illustrated by the lower mortality of, respectively, 5% and 6% in the studies
by GERSHON et al. [6] and AFONSO et al. [8], respectively. Other major differences from our study include the
fact that the studies by GERSHON et al. [6] and AFONSO et al. [8] excluded debuts of COPD after the age of
80 years, an approach that would have reduced our estimate by ,25% (fig. 2). Also, the two latter studies
used variable retrospective review periods of at least 1 year and at least 5 years, respectively. Reducing the
retrospective review period would increase our lifetime risk estimate as demonstrated. Making it variable,
e.g. from 8 years in 2002 to 14 years in 2008, would decrease the risk estimate slightly, but would introduce
a decreasing bias in the time trend. Finally, the GERSHON et al. [6] and VAN DURME et al. [7] estimates are
dated nearly one decade prior to ours and both the COPD incidence rates and mean life expectancies on
which they are based probably have changed since then.
Strengths and limitations
The major strengths of this study include the size and duration of the study, the complete coverage of an
entire nation, and the exact dates of hospitalisations, births and deaths. Also the homogenous equal access
TABLE 2 Residual lifetime risk of chronic obstructive pulmonary disease hospitalisation for 30-year-olds in Denmark during
the period 2002–2008
Period Females Males
Main definition Without pneumonia Exclusively J44 Main definition Without pneumonia Exclusively J44
2002 12.0 (9.7–14.4) 10.9 (8.4–13.3) 9.8 (6.4–13.3) 11.1 (10.2–11.9) 9.7 (8.1–13.4) 9.0 (7.5–10.5)
2003 11.9 (10.5–13.4) 10.7 (9.3–12.1) 9.5 (6.6–12.5) 11.1 (10.3–11.9) 9.6 (8.6–10.6) 8.5 (7.0–9.9)
2004 11.7 (11.0–12.5) 10.4 (8.9–11.9) 9.3 (7.8–10.9) 10.8 (9.7–12.0) 9.4 (8.0–10.7) 8.2 (7.0–9.5)
2005 12.4 (10.7–14.0) 11.1 (9.6–12.5) 9.9 (7.2–12.6) 10.9 (9.5–12.3) 9.4 (7.8–10.9) 8.5 (6.8–10.2)
2006 11.6 (11.0–12.2) 10.3 (9.1–11.5) 9.2 (8.1–10.3) 10.6 (9.9–11.4) 9.2 (8.2–10.2) 8.2 (7.3–9.0)
2007 12.4 (11.4–13.5) 11.1 (9.8–12.3) 9.6 (8.5–10.8) 11.4 (10.4–12.4) 9.8 (8.3–11.2) 8.4 (7.2–9.7)
2008 12.3 (11.3–13.3) 10.9 (9.0–12.8) 9.9 (8.0–11.7) 10.7 (9.8–11.7) 9.2 (8.6–9.8) 8.0 (6.7–9.3)
Pooled 12.0 (11.9–12.2) 10.7 (10.6–10.9) 9.6 (9.5–9.7) 10.9 (10.8–11.1) 9.4 (9.3–9.6) 8.4 (8.2–8.5)
Data are presented as % risk (95% CI).
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FIGURE 2 Accumulated incidence of
first-time chronic obstructive pulmonary
disease hospitalisation for 30-year-olds,
adjusted for the competing risk of death.
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free-of-charge Danish Healthcare system supports equality in the decision criteria to hospitalise across the
population.
The COPD diagnoses obtained from the registers were tested highly valid [14]. Nevertheless,
misclassification remains a potential limitation of our study, and no spirometry data were available to
further validate the diagnosis. Hence, our study includes some hospitalisations where the patients were
wrongly diagnosed with COPD. However, it probably also failed to include even more hospitalisations that
were caused by COPD, but miscoded with other diagnoses [14].
In large registers covering the general population, data on explaining factors, such as smoking status and
spirometry results, do not exist. Furthermore, any conclusion as to the lifetime risk of, e.g. smoking, would
require all the studied subjects to have maintained the same smoking status throughout the study period,
and could be reasonably assumed to maintain that exact status until death or the occurrence of the event
studied. Hence, regardless of study methods, for any risk factor besides sex, these requirements are nearly
always impossible to meet.
The lifetime risk of COPD hospitalisation varies among populations because of different incidences of
severe COPD exacerbations, different thresholds for admission to hospital, and different life expectancies.
For decades the proportion of daily smokers has been higher in Denmark relative to other developed
countries, especially among females [19]. Furthermore, the rate of COPD hospitalisations in Denmark [17]
is somewhat higher than in contemporary studies from the USA [20–22], Norway, Sweden [23] and France
[24]. Hence, compared with other developed countries, the lifetime risk of COPD hospitalisation is
probably higher in Denmark. However, the mean life expectancy in Denmark is the same as in the USA, but
shorter than in most European countries [19]. Shorter average lifespan means lower lifetime risk of all
diseases mainly occurring in old age. Therefore, generally healthier populations in other countries may have
even higher lifetime risks of COPD hospitalisation than in Denmark. The hospitalisation severity threshold
probably differs between countries. However, characteristics of Danish COPD hospitalisations are in line
15
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TABLE 3 Age-specific residual lifetime risk of chronic obstructive pulmonary disease hospitalisation in Denmark
Age years Females Males
Main definition Without
pneumonia
Exclusively J44 Main definition Without
pneumonia
Exclusively J44
30 12.0 (11.9–12.2) 10.7 (10.6–10.9) 9.6 (9.5–9.7) 10.9 (10.8–11.1) 9.4 (9.3–9.6) 8.4 (8.2–8.5)
40 12.0 (11.9–12.1) 10.7 (10.6–10.8) 9.6 (9.5–9.7) 11.0 (10.9–11.1) 9.4 (9.3–9.6) 8.4 (8.3–8.6)
50 11.8 (11.7–12.0) 10.5 (10.4–10.7) 9.5 (9.4–9.6) 11.0 (10.9–11.1) 9.5 (9.4–9.6) 8.5 (8.4–8.6)
60 11.3 (11.2–11.5) 10.1 (9.9–10.2) 9.1 (8.9–9.2) 10.9 (10.8–11.1) 9.4 (9.3–9.6) 8.4 (8.3–8.5)
70 9.6 (9.5–9.7) 8.5 (8.4–8.6) 7.6 (7.5–7.7) 10.2 (10.1–10.4) 8.7 (8.6–8.9) 7.8 (7.7–7.9)
80 5.3 (5.1–5.4) 4.5 (4.4–4.6) 4.0 (3.9–4.1) 7.0 (6.9–7.2) 5.8 (5.6–5.9) 5.1 (5.0–5.3)
90 1.5 (1.4–1.6) 1.2 (1.1–1.3) 1.0 (0.9–1.1) 2.3 (2.1–2.5) 1.7 (1.0–2.5) 1.5 (1.3–1.7)
Data are presented as % risk (95% CI).
FIGURE 3 Residual lifetime risk of
chronic obstructive pulmonary disease
hospitalisation.
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with other developed countries. For instance, the inpatient mortality, age, sex and length of stay regarding
COPD hospitalisations are similar in Denmark, the USA and the UK [9, 17, 25].
The main limitation of any lifetime risk study lies in the necessary assumption of time homogeneity
of incidence and mortality rates [2, 3]. Continuation of the increase in mean life expectancy, which
has been steady for more than two centuries [19, 26], will increase the lifetime risk of COPD
hospitalisation. Meanwhile, improved treatment possibilities and reductions in harmful airway exposure
will decrease it.
In Denmark, during our observation period, the total number of COPD hospitalisations as well as the age-
and sex-adjusted incidence rate of first-time cases decreased ,8% [17]. In the same period the incidence
and prevalence of hospitalisation-required COPD increased ,20% in the age group .80 years while
decreasing by ,20% in the age group below. These large bidirectional age-specific trends have been
explained as being due to the ageing of birth cohorts born around 1920, which were more exposed to both
cigarette smoke [27] and occupational dust than the birth cohorts born before and after [28]. Also, the low
exposure of the birth cohorts born before 1920 explains the observation from this study and others [8] that,
in the oldest age group, COPD incidence actually decreases with increasing age. Furthermore, during our
study period the ratio of patients treated with inhaled corticosteroids and tiotropium prior to their first
COPD hospitalisation improved substantially [17]. It is likely that this had a reductive effect on COPD
hospitalisation rates.
During our study period, there were some considerable changes in the Danish healthcare system. A 12%
reduction in the number of hospital beds for COPD patients and at the same time fewer hospitalisations
and increased inpatient mortality lead to the conclusion that the severity threshold for hospitalisation with
COPD increased [17].
During the period from 2002 to 2008, in both sexes, the concurrent underlying mixture of increasing
Danish overall life expectancy [19] and decreasing incidence rates of first-time COPD hospitalisations kept
the lifetime risk of COPD hospitalisation constant. This balance is unlikely to remain stable. It is, however,
unknown, whether increasing life expectancy or decreasing COPD incidence will be the stronger.
Estimates of mean life expectancy and lifetime risk are based on similar assumptions and thus have similar
features. In most populations, known birth cohort effects make the mean life expectancy a poor estimate of
the lifespan of a newborn. Likewise, the underlying changes in our study make the estimate for a 30-year-old
a less valid predictor than that for an 80-year-old. However, in a population, the mean life expectancy is
considered a valid indicator of general health and similarly, the lifetime risk of a disease is perhaps the
strongest and most robust indicator of its burden.
Conclusion
Based on present hospitalisation and survival rates, later in life .10% of all 30-year-old Danes will be
hospitalised with COPD. Trends were generally equal in both sexes. During the period from 2002 to 2008,
the rate of first-time COPD hospitalisations decreased, while the survival of never COPD hospitalised
subjects increased. As a consequence, the lifetime risk of COPD hospitalisation remained constant.
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